- Posted Thursday May 26, 2011
TGen study identifies compounds that could slow down Alzheimer's disease
Naturally occurring plant alkaloids could fend off potential
loss of memory
PHOENIX, Ariz. - May 26, 2011 - A family of naturally occurring plant compounds could help prevent or delay memory loss associated with Alzheimer's disease, according to a new study by the Translational Genomics Research Institute (TGen).
Beta-carboline alkaloids could potentially be used in therapeutic drugs to stop, or at least slow down, the progressively debilitating effects of Alzheimer's, according to the study published recently in the scientific journal Public Library of Science (PLoS) One.
One of these alkaloids, called harmine, inhibits a protein known as DYRK1A, which has been implicated by this and other studies in the formation tau phosphorylation. This process dismantles the connections between brain cells, or neurons, and has been linked in past TGen studies to Alzheimer's disease.
Tau is a protein critical to the formation of the microtubule bridges in neurons. These bridges support the synaptic connections that, like computer circuits, allow brain cells to communicate with each other.
"Pharmacological inhibition of DYRK1A through the use of beta-carboline alkaloids may provide an opportunity to intervene therapeutically to alter the onset or progression of tau pathology in Alzheimer's disease," said Dr. Travis Dunckley, Head of TGen's Neurodegenerative Research Unit, and the study's senior author.
Beta-carboline alkaloids are found in a number of medicinal plants. They have antioxidant properties, and have been shown to protect brain cells from excessive stimulation of neurotransmitters. "(They) are natural occurring compounds in some plant species that affect multiple central nervous system targets," the study said.
Under normal circumstances, proteins regulate tau by adding phosphates. This process of tau phosphorylation enables connections between brain cells to unbind and bind again, allowing neurons to connect and reconnect with other brain cells. However, this process can go awry, allowing the formation of neurofibrillary tangles, one of the signature indicators of Alzheimer's.
In this study, laboratory tests showed that harmine, and several other beta-carboline alkaloids, "potently reduced'' the expression of three forms of phosphorylated tau, and inhibited the ability of DYRK1A to phosphorylate tau protein at multiple genetic sites associated with tau pathology.
"These results suggest that this class of compounds warrant further investigation as candidate tau-based therapeutics to alter the onset or progression of tau dysfunction and pathology in Alzheimer's disease," Dr. Dunckley said.
The Arizona Alzheimer's Consortium, the National Institute on Aging, and the Louis Charitable Trust funded the study. The Consortium is funded in part by the Arizona Legislature through the Arizona Department of Health Services, which supported a portion of the study. Members of the Consortium also participated in the study. MediProPharma Inc. supported portions of the study.
PLoS is a non-profit organization of scientists and physicians committed to making the world's scientific and medical literature a freely available public resource.
# # #
About the Arizona Alzheimer's Consortium
The Arizona Alzheimer's Consortium is a 501(c)(3) organization that includes the state-supported Arizona Alzheimer's Research Center (AARC), the National Institute on Aging (NIA)-funded Arizona Disease Core Center (Arizona ADCC), and independently funded research programs. Its seven member institutions include: Arizona State University, Barrow Neurological Institute, Mayo Clinic Arizona, Banner Sun Health Research Institute, the Translational Genomics Research Institute (TGen), the University of Arizona, and Banner Alzheimer's Institute. Its three affiliated institutions include Banner Good Samaritan Medical Center, the Southern Arizona Veterans Administration Health Care System and the University Physician's Hospital at Kino. For more information, including the consortium's upcoming scientific conference, go to: www.azalz.org.
The Translational Genomics Research Institute (TGen) is a Phoenix, Arizona-based non-profit organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. TGen is affiliated with the Van Andel Research Institute in Grand Rapids, Michigan. For more information, visit: www.tgen.org.
TGen Senior Science Writer